首页 > 市场调查报告书 > 製药

药物开发开发业务受託机关

市场调查报告书

商品编码

1900697

药物研发外包市场规模、份额及成长分析（按药物类型、治疗领域、最终用户及地区划分）－2026-2033年产业预测

Drug Discovery Outsourcing Market Size, Share, and Growth Analysis, By Drug Type (Small Molecules, Large Molecules), By Therapeutics Area (Oncology, Diabetes), By End User,, By Region -Industry Forecast 2026-2033

出版日期: 2025年12月18日 | 出版商:

SkyQuest | 英文 242 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计到 2024 年，药物研发外包市场规模将达到 38.6 亿美元，到 2025 年将达到 41.4 亿美元，到 2033 年将达到 72.2 亿美元，在预测期（2026-2033 年）内，复合年增长率为 7.2%。

由于外包成本高且监管严格，药物研发外包市场面临许多挑战。然而，癌症和慢性病发病率上升、人口老化、法律环境趋于宽鬆，以及开发中国家）更容易获得价格合理且技能精湛的劳动力等因素，都为市场提供了成长机会。行业相关人员正在调整策略，以在不断变化的环境中保持市场份额。製药业正经历重大变革，包括向生物製药的转型和专利到期，这些都正在改变传统的商业模式。透过专注于先导化合物确认和先导药物最适化等阶段的专业化，企业可以增强其核心竞争力。研发投入的成长、对创新药物研发方法的需求以及人工智慧等技术的进步，都在加速外包趋势的发展。

药物研发外包市场按工作流程、治疗领域、药物类型、服务类型、最终用户和地区进行细分。依工作流程划分，市场分为标靶识别和筛检、标靶检验和功能资讯学、先导化合物识别和候选药物优化、临床前开发等相关工作流程。依治疗领域划分，市场分为呼吸系统、疼痛和麻醉、肿瘤、眼科、循环系统、心臟病学、内分泌学、胃肠病学、免疫调节、抗感染、中枢神经系统、皮肤病学和泌尿生殖系统。依药物类型划分，市场分为小分子药物和大分子药物（生物製药）。按服务类型划分，市场分为化学服务和生物学服务。按最终用户划分，市场分为製药和生技公司、学术机构和其他机构。依地区划分，市场分为北美、欧洲、亚太、拉丁美洲以及中东和非洲。

药物研发外包市场驱动因素

製药业日益增长的成本削减需求是药物研发外包市场发展的关键驱动因素。该行业的公司不断寻求优化营运并增加研发投入。透过将标靶分子鑑定、筛检、先导化合物优化和临床前试验等药物研发活动外包给外部合作伙伴，製药公司可以大幅降低库存、人事费用和管理费用。这种方式不仅使他们能够获得受託研究机构(CRO) 提供的先进技术、一流设施和专业知识，还能加速药物研发进程。最终，这种模式能够带来显着且可持续的营运和财务优势，从而在生物製药行业中得到广泛应用。

药物研发外包市场的限制因素

由于监管和合规风险可能阻碍成长，药物研发外包市场面临严峻挑战。各国在临床试验、资料管理和产品开发方面的监管要求存在差异，这为企业带来了许多障碍。严格遵守良好实验室规范 (GLP) 和良好临床规范 (GCP) 等标准对于预防监管问题和确保药物研发流程的完整性至关重要。此外，遵守这些法规的复杂性和耗时性可能会使一些企业放弃外包方案，从而影响整体市场扩张和参与度。

药物研发外包市场趋势

受基因疗法和细胞疗法等创新疗法在治疗复杂慢性疾病方面日益显着的疗效推动，生物製药领域的药物研发外包市场正呈现显着成长。生物製药公司逐渐意识到自身研发能力的局限性，并开始寻求专业CRO（合约委外研发机构）和CDMO（合约开发和受託製造厂商）的协助。这一趋势凸显了市场对客製化外包服务的日益增长的需求，这些服务能够简化药物研发流程、提高产品品质并缩短上市时间。生物製药外包的兴起反映了该行业致力于在快速变化的医疗环境中推动治疗方法的进步。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲（MEA）
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争格局

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市集活动
主要企业市占率（2025 年）

主要企业简介

Charles River Laboratories International, Inc.
WuXi AppTec Co., Ltd.
Laboratory Corporation of America Holdings（LabCorp）
Evotec SE
Covance Inc.
Thermo Fisher Scientific Inc.
Eurofins Scientific
Pharmaron Beijing Co., Ltd.
Syngene International Ltd.
Genscript Biotech Corporation
ChemPartner
Jubilant Biosys Ltd.
ICON plc
QuintilesIMS（IQVIA）
Cambrex Corporation
Viva Biotech
Domainex Ltd.
Curia Global, Inc.（formerly Albany Molecular Research, Inc.）
Tecan Group Ltd.
Shanghai Medicilon Inc.

简介目录

Product Code: SQMIG35C2011

Drug Discovery Outsourcing Market size was valued at USD 3.86 Billion in 2024 and is poised to grow from USD 4.14 Billion in 2025 to USD 7.22 Billion by 2033, growing at a CAGR of 7.2% during the forecast period (2026-2033).

The drug discovery outsourcing market is facing challenges due to high outsourcing costs and stringent regulations. However, emerging opportunities exist, particularly in developing countries, where factors like rising incidences of cancer and chronic diseases, an aging population, a more favorable legal environment, and access to affordable, skilled labor with advanced knowledge present avenues for growth. Industry professionals are adapting strategies to maintain market share amid the evolving landscape. The pharmaceutical sector has experienced significant transformations, with shifts in biopharmaceuticals and patent expirations impacting traditional models. By focusing on specialization in stages like hit confirmation and lead optimization, companies can enhance core competencies. The increasing R&D costs and demand for innovative drug discovery methods, alongside advancements like AI, are propelling the trend toward outsourcing.

Top-down and bottom-up approaches were used to estimate and validate the size of the Drug Discovery Outsourcing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Drug Discovery Outsourcing Market Segments Analysis

Drug Discovery Outsourcing Market is segmented by Workflow, Therapeutics Area, Drug Type, Service Type, End User, and region. Based on Workflow, the market is segmented into Target Identification & Screening, Target Validation & Functional Informatics, Lead Identification & Candidate Optimization, Preclinical Development, and Other Associated Workflow. Based on Therapeutics Area, the market is segmented into Respiratory system, Pain and Anesthesia, Oncology, Ophthalmology, Hematology, Cardiovascular, Endocrine, Gastrointestinal, Immunomodulation, Anti-infective, Central Nervous System, Dermatology, and Genitourinary System. Based on Drug Type, the market is segmented into Small Molecules, Large Molecules (Biopharmaceuticals). Based on Service Type, the market is segmented into Chemistry Services, Biology Services. Based on End User, the market is segmented into Pharmaceutical & Biotechnology companies, Academic Institutes, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Drug Discovery Outsourcing Market

The growing need to minimize costs in the pharmaceutical sector is a significant driver for the drug discovery outsourcing market. Companies in this industry continually strive to optimize their operations and enhance their research and development investments. By delegating drug discovery tasks such as target identification, screening, lead optimization, and preclinical testing to external partners, pharmaceutical firms can considerably lower their inventory, labor, and overhead expenses. This approach not only grants access to the advanced technology, cutting-edge equipment, and specialized knowledge offered by contract research organizations, but also accelerates the drug discovery process. Ultimately, this model delivers substantial and enduring operational and financial advantages that facilitate its acceptance within the biopharmaceutical landscape.

Restraints in the Drug Discovery Outsourcing Market

The Drug Discovery Outsourcing market faces significant challenges due to regulatory and compliance risks that can hinder its growth. Variations in regulatory requirements across countries for clinical trials, data management, and product development create obstacles for companies. Adhering to strict standards, such as Good Laboratory Practices (GLP) and Good Clinical Practices (GCP), is crucial to prevent regulatory issues and ensure the integrity of the drug development process. Additionally, the complexity and time-consuming nature of navigating these regulations can deter some companies from pursuing outsourcing options, thereby affecting overall market expansion and participation.

Market Trends of the Drug Discovery Outsourcing Market

The drug discovery outsourcing market is experiencing a significant shift toward biopharmaceutical outsourcing, driven by the increasing efficacy of innovative therapies such as gene and cell-based treatments for complex chronic diseases. As biopharmaceutical companies recognize their limitations in in-house product development capabilities, they are seeking the expertise of specialized Contract Research Organizations (CROs) and Contract Development and Manufacturing Organizations (CDMOs). This trend underscores a growing demand for tailored outsourcing services that streamline the drug discovery process, enhance product quality, and reduce time to market. The evolution towards biopharmaceutical outsourcing reflects the industry's commitment to advancing therapeutics in a rapidly changing healthcare landscape.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factor
Degree of Competition
Top Investment Pockets
Ecosystem of the Market
Regulatory Analysis
Case Study Analysis

Drug Discovery Outsourcing Market, By Workflow

Market Overview
Target Identification & Screening
Target Validation & Functional Informatics
Lead Identification & Candidate Optimization
Preclinical Development
Other Associated Workflow

Drug Discovery Outsourcing Market, By Therapeutics Area

Market Overview
Respiratory system
Pain and Anesthesia
Oncology
Ophthalmology
Hematology
Cardiovascular
Endocrine
Gastrointestinal
Immunomodulation
Anti-infective
Central Nervous System
Dermatology
Genitourinary System

Drug Discovery Outsourcing Market, By Drug Type

Market Overview
Small Molecules
Large Molecules (Biopharmaceuticals)

Drug Discovery Outsourcing Market, By Service Type

Market Overview
Chemistry Services
Biology Services

Drug Discovery Outsourcing Market, By End User

Market Overview
Pharmaceutical & Biotechnology companies
Academic Institutes
Others

Drug Discovery Outsourcing Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2025

Key Company Profiles

Charles River Laboratories International, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
WuXi AppTec Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Laboratory Corporation of America Holdings (LabCorp)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Evotec SE
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Covance Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eurofins Scientific
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pharmaron Beijing Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Syngene International Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Genscript Biotech Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ChemPartner
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Jubilant Biosys Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ICON plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
QuintilesIMS (IQVIA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cambrex Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Viva Biotech
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Domainex Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Curia Global, Inc. (formerly Albany Molecular Research, Inc.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Tecan Group Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Shanghai Medicilon Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments